Lyra Therapeutics, Inc.

LYRA Healthcare Biotechnology

Lyra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $398,000.00, down 74.1% from fiscal 2024. In the quarter to December 2025, revenue fell 96.7%, EPS grew 53.0% and free cash flow grew 45.4%, each against the same quarter a year earlier.

0.19 0.00 0.00%
Market cap
$870.0K
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−19.35
Beneish M
n/a
Dividend safety
n/a
Dec '25 Sep '25 Jun '25 Mar '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
12.02 19.24 15.70 7.01
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(0.79) (1.57) (1.83) (0.94)
P/B ratio
0.00 0.00 7.45 2.15
EV/Sales
(27.91) (17.52) (22.98) (19.77)
EV/EBITDA
0.36 0.30 0.42 0.28
EV/FCF
0.38 0.31 0.41 0.40
Current Ratio
1.71 2.43 2.78 2.96
Net Debt/EBITDA
2.26 3.60 3.42 3.64
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(621.75%) (358.19%) (323.77%) (957.28%)
Free Cash Flow Yield
(604.17%) (295.71%) (357.39%) (706.64%)
Free Cash Flow per Share
(3.97) (4.16) (4.89) (6.72)
Book value per Share
(6.90) (2.45) 1.20 2.94
Free Cash Flow
(6.16) (7.36) (6.59) (8.84)
EV/EBIT
0.36 0.30 0.43 0.29
Other line items

Show all line items

Columns are period end dates